By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


NGM Biopharmaceuticals, Inc. 

630 Gateway Boulevard

South San Francisco  California  94080-7014  U.S.A
Phone: 650-243-5555 Fax: 650-583-1646


Company News
NGM Announces NGM282 Dramatically Reduced Liver Fat And Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) In Phase II Trial 4/24/2017 7:33:56 AM
NGM Initiates Phase 1 Clinical Trial Of NGM313, A Proprietary Antibody With The Potential To Treat Type 2 Diabetes, Obesity And NASH 6/8/2016 7:29:15 AM
Nine Bay Area Biotechs Vie to be the “Next Genentech (RHHBY)” 5/24/2016 6:33:42 AM
Booming Bay Area Biotech NGM Plans Move to Vacant Site Once Meant for Amgen (AMGN) 5/4/2016 6:16:12 AM
NGM To Present New Data On NGM282 At The European Association For The Study Of The Liver International Liver Congress 2015 4/20/2015 2:21:37 PM
NGM Announces Positive Phase II Clinical Data In Primary Biliary Cirrhosis Patients For NGM282, A First-In-Class Investigational Medicine 3/24/2015 7:19:41 AM
Backed By a Genentech (RHHBY) Alum, NGM Looks Like it Could be the Next Biotech IPO 3/3/2015 6:24:13 AM
NGM Announces Expansion Of Management Team 3/2/2015 7:58:32 AM
How Merck & Co. (MRK)'s R&D Chief Saved NGM Deal With a Juicy Pitch 2/24/2015 6:23:05 AM
Merck & Co. (MRK) Bets $450 Million on Bay Area's NGM 2/23/2015 5:59:08 AM